Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
RTOG 0933
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
- NCT01227954 ↗
- Completed
- Radiation Therapy Oncology Group
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on RTOG 0933 (brain metastases; tests a strategy, not a drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RTOG 0933 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X | |
| 1 YouTube video |
The trial
ClinicalTrials.gov- Official title
- A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Cognitive/Functional Effects; Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- intensity-modulated radiation therapy
- Arms
- WBRT with Hippocampal Avoidance · Other
- Enrollment
- 113
- Primary outcomes
- Percent Change in Delayed Recall at 4 Months as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R)
- Sponsor
- Radiation Therapy Oncology Group with National Cancer Institute (NCI), NRG Oncology
- Start
- Mar 2011
- Primary completion
- May 2013
- Results posted
- Yes
- Registry record
- NCT01227954 · updated Sep 27, 2017
Publications
linked from the registry- Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, Rowley H, Kundapur V, DeNittis A, Greenspoon JN, Konski AA, Bauman GS, Shah S, Shi W, Wendland M, Kachnic L, Mehta MP. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014 Dec 1;32(34):3810-6. doi: 10.1200/JCO.2014.57.2909. Epub 2014 Oct 27. PubMed 25349290